ALX Oncology Holdings (ALXO) has shared an announcement.
ALX Oncology Holdings Inc. boosted its board’s expertise by appointing Dr. Alan Sandler as a Class III director, with a term ending in 2026. Dr. Sandler, with a rich background in oncology including executive roles at Mirati Therapeutics and Genentech, and academic positions at prestigious universities, is set to contribute to the Audit and Compensation Committees. His experience deemed him independent according to SEC and Nasdaq standards, allowing the company to meet Nasdaq’s requirement for a majority of independent directors. The board’s size was adjusted to six following the resignations of Drs. Pons and Randolph, who remain in senior company positions.
For detailed information about ALXO stock, go to TipRanks’ Stock Analysis page.
